Afficher la notice abrégée

Metabolomics in serum of patients with non-advanced age-related macular degeneration reveals aberrations in the glutamine pathway.

dc.rights.licenseopenen_US
dc.contributor.authorKERSTEN, Eveline
dc.contributor.authorDAMMEIER, Sascha
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorAJANA, Soufiane
dc.contributor.authorGROENEWOUD, Joannes M M
dc.contributor.authorCODREA, Marius
dc.contributor.authorKLOSE, Franziska
dc.contributor.authorLECHANTEUR, Yara T
dc.contributor.authorFAUSER, Sascha
dc.contributor.authorUEFFING, Marius
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDELCOURT, Cecile
dc.contributor.authorHOYNG, Carel B
dc.contributor.authorDE JONG, Eiko K
dc.contributor.authorDEN HOLLANDER, Anneke I
dc.date.accessioned2020-04-02T09:47:50Z
dc.date.available2020-04-02T09:47:50Z
dc.date.issued2019-06-21
dc.identifier.issn1932-6203en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/4072
dc.description.abstractEnAge-related macular degeneration (AMD) is a common, progressive multifactorial vision-threatening disease and many genetic and environmental risk factors have been identified. The risk of AMD is influenced by lifestyle and diet, which may be reflected by an altered metabolic profile. Therefore, measurements of metabolites could identify biomarkers for AMD, and could aid in identifying high-risk individuals. Hypothesis-free technologies such as metabolomics have a great potential to uncover biomarkers or pathways that contribute to disease pathophysiology. To date, only a limited number of metabolomic studies have been performed in AMD. Here, we aim to contribute to the discovery of novel biomarkers and metabolic pathways for AMD using a targeted metabolomics approach of 188 metabolites. This study focuses on non-advanced AMD, since there is a need for biomarkers for the early stages of disease before severe visual loss has occurred. Targeted metabolomics was performed in 72 patients with early or intermediate AMD and 72 control individuals, and metabolites predictive for AMD were identified by a sparse partial least squares discriminant analysis. In our cohort, we identified four metabolite variables that were most predictive for early and intermediate stages of AMD. Increased glutamine and phosphatidylcholine diacyl C28:1 levels were detected in non-advanced AMD cases compared to controls, while the rate of glutaminolysis and the glutamine to glutamate ratio were reduced in non-advanced AMD. The association of glutamine with non-advanced AMD corroborates a recent report demonstrating an elevated glutamine level in early AMD using a different metabolomics technique. In conclusion, this study indicates that metabolomics is a suitable method for the discovery of biomarker candidates for AMD. In the future, larger metabolomics studies could add to the discovery of novel biomarkers in yet unknown AMD pathways and expand our insights in AMD pathophysiology.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/us/
dc.subjectAged
dc.subjectBiomarkers
dc.subjectDiscriminant Analysis
dc.subjectFemale
dc.subjectGlutamine
dc.subjectHumans
dc.subjectLeast-Squares Analysis
dc.subjectMacular Degeneration
dc.subjectMetabolic Networks and Pathways
dc.subjectMetabolomics
dc.subjectMiddle Aged
dc.titleMetabolomics in serum of patients with non-advanced age-related macular degeneration reveals aberrations in the glutamine pathway.
dc.title.alternativePLoS Oneen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1371/journal.pone.0218457en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed31220133en_US
bordeaux.journalPLoS ONEen_US
bordeaux.pagee0218457en_US
bordeaux.volume14en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamHEALTHY_BPH
bordeaux.teamLEHA_BPH
bordeaux.teamLEHA_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-02529335
hal.version1
hal.date.transferred2020-04-02T09:54:46Z
hal.exporttrue
workflow.import.sourcepubmed
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.title=Metabolomics%20in%20serum%20of%20patients%20with%20non-advanced%20age-related%20macular%20degeneration%20reveals%20aberrations%20in%20the%20glutamine%20pathway.&rft.atitle=Metabolomics%20in%20serum%20of%20patients%20with%20non-advanced%20age-related%20macular%20degeneration%20reveals%20aberrations%20in%20the%20glutamine%20pathway.&rft.jtitle=PLoS%20ONE&rft.date=2019-06-21&rft.volume=14&rft.issue=6&rft.spage=e0218457&rft.epage=e0218457&rft.eissn=1932-6203&rft.issn=1932-6203&rft.au=KERSTEN,%20Eveline&DAMMEIER,%20Sascha&AJANA,%20Soufiane&GROENEWOUD,%20Joannes%20M%20M&CODREA,%20Marius&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_PO_2019_Kersten.pdf
Taille:
999.1Ko
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée